Biological CubeSats planned by Vector Space Biosciences

Vector Space Biosciences has begun filing for licensing and registration for the design, development and launching of biological CubeSats, enabling biotechnology, pharmaceutical and advanced materials companies to generate unique and powerful datasets to advance the space industry.

For humans to establish a lunar base or go to Mars, understanding how to protect and repair the human body during spaceflight is necessary. Spaceflight includes a variety of stressors to the human body, including microgravity and radiation in the form of Galactic Cosmic Rays (GCRs) and HZE particles, the high-energy nuclei component of GCRs. These stressors result in damage to the human body. Vector Space Biosciences, along with its technical and scientific collaborators including Oracle, NVIDIA, Lawrence Berkeley National Lab (LBNL/DOE), Imperial College of London (ICL), University College London (UCL), Cal Poly Pomona, University of California San Diego (UCSD), IFO Rome, City of Hope, McGill University and others, will leverage advanced language modeling/AI (Artificial Intelligence) techniques – including context-dependent hidden relationship detection between proteins, pathways, drug compounds and molecular sequences – to enable new hypotheses, insights, interpretations and discoveries to counteract these stressors.

Vector Space Biological CubeSats will Launch from Vandenberg

Vector Space Biosciences maintains three divisions: a biosciences lab, AI, Language Modeling & Discovery lab, and hardware lab. Resulting products are designed to generate new discoveries and accelerate existing ones. This will include design and development of biological CubeSats launched from Vandenberg Space Force base into Low Earth Orbit (LEO), initially, followed by deep space missions, for the purpose of enabling biotechs, pharmas and advanced materials customers to conduct experiments in microgravity and radiation resulting in better efficacy for drug development. Data will be analyzed and interpreted using proprietary advanced language modeling/AI and visualizations that apply to a variety of industries, including biotechnology, pharmaceutical, advanced materials, and the financial markets.

Vector Space Biosciences is working with NASA BioSentinel program, NASA Flight Operations, Advacam, SpaceX Rideshare, Exolaunch, Cal Poly - Bronco Space, and Microsoft Azure Space to eventually enable multiple launches per week for a wide array of customers.

All biological experimental focuses are based on the deep knowledge domain expertise of our Scientific Advisory Board (SAB), network of scientific labs and collaborators. Revenue streams result from packages and services offered by the Biological CubeSat Launch Platform (BCLP) along with datasets subscription services.

Dataset security and provenance are managed using the blockchain. Datasets represent a significant attack vector in AI today as datasets power all AI. If a correlation value changes in a dataset it could lead to loss of life for a pharmaceutical company developing new drug compounds or a loss in billions for a hedge fund reliant on accurate calculations. The VXV utility token is used to transact all dataset updates via the VXV wallet-enabled API.

Customers are invited to pre-register for missions aboard these biological CubeSats now and during the Vector Space Biosciences talk at Oracle Health Conference on September 20th, 2023.

(Source: Vector Space Biosciences news release. Image from file)